{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:44:48Z","timestamp":1791902688563,"version":"4.3.4"},"reference-count":31,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with alopecia areata (AA) in ALLEGRO\u20102b\/3 (NCT03732807) had clinically significant hair regrowth and patient\u2010reported improvements with ritlecitinib versus placebo, but patient\u2010reported improvements in AA Patient Priority Outcomes (AAPPO) emotional symptoms (ES) or activity limitations (AL) were not observed during the 24\u2010week placebo\u2010controlled phase. This study compared AAPPO scores between the 50\u2010mg ritlecitinib maintenance dose (+\/\u2212\u2009200\u2010mg 4\u2010week loading dose) and subtherapeutic 10\u2010mg ritlecitinib through Week 48 of ALLEGRO\u20102b\/3.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Least squares mean (LSM) changes from baseline (CFBs) in domain scores were estimated for the full analysis population and for participants with baseline domain scores \u2265\u20091. Item\u2010level responses (scores &lt;\u20092) were evaluated for participants with baseline item scores \u2265\u20092, since lower baseline item scores (measured on 5\u2010point response scales; range, 0\u20134) indicated less frequent\/severe impacts from hair loss.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There were 325 participants (200\/50\u2010mg [\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009132] and 50\u2010mg [\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009130], combined and as subgroups; 10\u2010mg [\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200963]). LSM CFBs in ES and AL domain scores generally improved through Week 48 for all 50\u2010mg groups, with significant differences versus 10\u2010mg starting at Week 34 for ES and Week 40 for AL. The proportion of responders for all ES and AL items generally increased through Week 48 for all 50\u2010mg groups. The largest improvements versus 10\u2010mg were for ES items 5 and 6 (self\u2010consciousness and embarrassment) and AL item 11 (interactions with others).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ALLEGRO\u20102b\/3 participants reported greater improvements in ES and AL due to hair loss by Week 48 with the 50\u2010mg ritlecitinib maintenance dose (+\/\u2212\u2009200\u2010mg loading dose) versus subtherapeutic 10\u2010mg ritlecitinib.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ijd.70035","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T04:17:58Z","timestamp":1760069878000},"page":"526-534","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Improvement in Patient\u2010Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From\n                    <scp>ALLEGRO<\/scp>\n                    \u20102b\/3"],"prefix":"10.1111","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6111-8008","authenticated-orcid":false,"given":"Ernest H.","family":"Law","sequence":"first","affiliation":[{"name":"Pfizer, Inc.  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3251-0078","authenticated-orcid":false,"given":"Bintu","family":"Sherif","sequence":"additional","affiliation":[{"name":"RTI Health Solutions  North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6084-5617","authenticated-orcid":false,"given":"Arash","family":"Mostaghimi","sequence":"additional","affiliation":[{"name":"Department of Dermatology Brigham &amp; Women's Hospital, Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4576-4616","authenticated-orcid":false,"given":"Brett","family":"King","sequence":"additional","affiliation":[{"name":"Department of Dermatology Yale University  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6751-1428","authenticated-orcid":false,"given":"Rodney","family":"Sinclair","sequence":"additional","affiliation":[{"name":"Sinclair Dermatology  East Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2705-7002","authenticated-orcid":false,"given":"Natasha","family":"Mesinkovska","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of California, Irvine  California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7201-3324","authenticated-orcid":false,"given":"Kent A.","family":"Hanson","sequence":"additional","affiliation":[{"name":"Pfizer, Inc.  New York New York USA"},{"name":"Department of Pharmacy Systems, Outcomes and Policy University of Illinois Chicago  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1147-7532","authenticated-orcid":false,"given":"Dane","family":"Korver","sequence":"additional","affiliation":[{"name":"RTI Health Solutions  North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7495-382X","authenticated-orcid":false,"given":"Costel","family":"Chirila","sequence":"additional","affiliation":[{"name":"RTI Health Solutions  North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1103442"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.11"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.032"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/ccid.S376096"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.04.1141"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.05.008"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.1950.52"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(23)00222\u20102"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18926"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijt.ijt_99_20"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijt.ijt_93_18"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010022\u201000864\u20101"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010021\u201000512\u20100"},{"key":"e_1_2_11_15_1","unstructured":"Pfizer Laboratories Division of Pfizer Inc. \u201cLITFULO\u2010Ritlecitinib Capsule Prescribing Information \u201d(2023) https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=19638."},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010023\u201001928\u2010y"},{"key":"e_1_2_11_17_1","unstructured":"European Medicines Agency (EMA) \u201cLitfulo (Ritlecitinib) \u201d(2023) https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/litfulo."},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jisp.2020.05.007"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/1359105308097954"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000530076"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.5732"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010023\u201000941\u2010z"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010021\u201000648\u2010z"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.06.308"},{"key":"e_1_2_11_25_1","unstructured":"E. H.Law B.Sherif N. J.Williams et\u00a0al. \u201cImprovements in Patient\u2010Reported Outcomes Based on Scalp Hair Regrowth Among Patients With Alopecia Areata: Analysis of the ALLEGRO 2b\/3 Trial \u201dPaper Presented at: 31st European Academy of Dermatology & Venereology (EADV) Congress (2022)."},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010021\u201000508\u2010w"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19768"},{"key":"e_1_2_11_28_1","unstructured":"US Food and Drug Administration (FDA) \u201cFDA Approves First Systemic Treatment for Alopecia Areata \u201d(2022) https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010approves\u2010first\u2010systemic\u2010treatment\u2010alopecia\u2010areata."},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljac059"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.9b00188"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110343"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt\u20102023\u20100069"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.70035","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijd.70035","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.70035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T09:51:10Z","timestamp":1772963470000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.70035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1111\/ijd.70035"],"URL":"https:\/\/doi.org\/10.1111\/ijd.70035","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"assertion":[{"value":"2025-06-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}